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Telomeres are tandem repeats of the
noncoding DNA structures at the end of
human chromosomes that protect the
coding DNA and the integrity of the
genome (Blackburn, 1991). The ability
to sustain telomere length confers un-
limited proliferative capacity to cancer
cells. In most cancers telomere length is
maintained by the activity of the
enzyme telomerase (Kim et al., 1994),
whose catalytic subunit is encoded by
the telomerase reverse transcriptase
(TERT) gene. However, until recently,
the underlying mechanisms for telo-
merase activation in cancer cells were
largely unknown.
Recurrent transcription activating
mutations of the TERT promoter were
first described in melanoma and sub-
sequently in other tumor types (Horn
et al., 2013; Vinagre et al., 2013).
These mutations upregulate TERT
expression by recruiting the multimeric
GA-binding protein transcription factor
that specifically binds to the mutant
promoter (Bell et al., 2015). In addition
to the mutations, DNA methylation of
the TERT promoter is likely to play a
role in TERT expression (Guilleret and
Benhattar, 2004). More recently it was
shown that a region of the TERT pro-
moter upstream of the transcription start
site is methylated in malignant
telomerase-expressing pediatric brain
tumors but not in telomerase-negative
normal brain tissue or low-grade
tumors (Castelo-Branco et al., 2013).
We previously showed that an
aggressive form of pediatric melanoma
developing within giant congenital nevi
(GCN) retains the wild-type TERT pro-
moter (Lu et al., 2015). To determine
whether epigenetic modifications may
play a role in telomerase expression in
this melanoma subtype, we analyzed
the DNA methylation profile of a CpG-Abbreviations: GCN, giant congenital nevi; TERT, te
Accepted manuscript published online 24 Septemberrich region of the TERT promoter,
shown previously to be differentially
methylated between normal and ma-
lignant tissues (Castelo-Branco et al.,
2013), in 13 melanomas (3 arising in
GCN, 7 conventional, and 3 spitzoid)
and 10 benign or borderline melano-
cytic tumors (1 GCN, 3 GCN with
nodular proliferation, and 6 borderline
spitzoid melanocytic neoplasms) from
23 pediatric and adult patients. The
human investigations were performed
after approval by local institutional re-
view boards. Written, informed patient
consent was waived because the
research involved no more than mini-
mal risk to the subjects. The status of
the TERT promoter, BRAF and NRAS
mutations, and kinase fusions was
available for the spitzoid tumors and a
subset of melanoma samples from our
prior studies (Lee et al., 2015; Lu et al.,
2015).
Supplementary Table S1 (online) and
Figure 1 summarize the demographic
and outcome data and the primary
driver oncogene for the 23 study sub-
jects. PCReSanger sequencing identi-
fied a hotspot TERT promoter mutation
(4 C228T [chr5:1,295,228], 3 C250T
[chr5: 1,295,250], and 2 CC242/243TT
[chr5: 1,295,242-3]) in 9 of 13 mela-
noma samples (6/7 conventional; 3/3
spitzoid; 0/3 melanomas in GCN) but
not in the 10 benign or borderline
melanocytic neoplasms (Figure 1). The
DNA methylation status of a region of
the TERT promoter, from 482 bp to 667
bp upstream of the ATG start site (chr5:
12955861295771 [GRCh37/hg19])
(see Supplementary Figure S1, online),
encompassing 26 CpG sites, was
assayed by next-generation bisulfite
sequencing (see Supplementary
Methods, online). For each CpG site,
the methylation ratio (beta value) was
measured in the range of 0 to 1 (seelomerase reverse transcriptase (gene)
2015Supplementary Table S2, online). The
methylation status was defined as fol-
lows: >0.7, methylated (Figure 1, red);
0.5 to 0.7, partially methylated (or-
ange); 0.3 to <0.5, partially unmethy-
lated (cyan); and <0.3, unmethylated
(blue). Supplementary Table S3 (online)
shows the total number of methylated
Cs and unmethylated Cs in the
sequenced region for each sample.
Remarkably, almost all 26 CpG sites in
the sequenced region were highly
methylated in the three melanomas
arising in GCN (S1, S2, S21) and in the
one conventional melanoma bearing
wild-type TERT promoter (S22),
whereas the CpG sites remained pre-
dominantly unmethylated in the 9
mutant TERT promoter melanomas and
the 10 benign or borderline melano-
cytic neoplasms (Figure 1).
Next, we evaluated the association of
TERT promoter CpG methylation with
telomerase expression by TERT mRNA
in situ hybridization and by gene
expression analysis (Supplementary
Methods). TERT mRNA in situ hybridi-
zation revealed distinct, intracellular
punctate signals in melanomas arising
in GCN (Figure 2c and f) but not in the
proliferative nodules in GCN (Figure 2i
and l). The TERT promoter methylation
level was calculated as the log 2 ratio of
the total number of methylated Cs
versus the total number of unmethy-
lated Cs in the sequenced region (logit
[beta value]). The TERT expression level
was measured by using RNA
sequencing data available for a subset
of samples. An association analysis
revealed a strong correlation between
TERT promoter methylation and TERT
expression level (P ¼ 0.0422, adjusted
r2 ¼ 0.5145; see Supplementary
Figure S2, online).
Our data demonstrate that epigenetic
modification through TERT promoter
CpG methylation is an alternative
pathway for TERT reactivation in mel-
anoma. Although epigenetic remodel-
ing by promoter methylation iswww.jidonline.org 339
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Figure 1. Association of the mutational status and the methylation profile of the TERT promoter with disease characteristics and outcome data for 23 patients
with melanocytic tumors. The 26 CpG sites were aberrantly methylated in wild-type TERT promoter melanomas (the last four rows) but were predominantly
unmethylated in low-grade or benign melanocytic tumors (atypical spitzoid neoplasms and GCN with proliferative nodules) and in mutant TERT promoter
melanomas. Methylation panel color code: M, methylated; PM, partially methylated; PUM, partially unmethylated; UM, unmethylated; NA, not available.
Y Fan et al.
TERT Promoter Hypermethylation in Melanoma
340generally considered a signature of
gene silencing, TERT expression is
paradoxically increased by promoter
methylation (Guilleret and Benhattar,
2004). Although the exact mechanism
underlying CpG DNA methylation in
TERT upregulation is not known, one
possible mechanism is by inhibiting
transcriptional repressors such as CTCFJournal of Investigative Dermatology (2016), Volum(Renaud et al., 2007), SIN3A , or MAZ
(Xu et al., 2013) from binding to the
target DNA-binding sites in the region
(Supplementary Figure S1). Also, even
when the promoter is largely methyl-
ated, a small region of the core pro-
moter upstream of the transcription start
site remains unmethylated to allow for
the continued transcriptional activity ofe 136TERT (Renaud et al., 2007; Zinn et al.,
2007).
Individuals with GCN are at
increased risk for developing melanoma
(Figure 2a, b, d, and e) that occurs most
frequently in the first decade of life
(Bittencourt et al., 2000). A much more
frequent change in these nevi than
melanoma is the development of clonal
Figure 2. Representative photomicrographs of H&E-stained histological sections and TERT mRNA in situ hybridization. The two top panels represent two
melanomas in GCN and the two bottom panels represent two proliferative nodules in GCN. mRNA in situ hybridization shows numerous high-resolution red
intracellular punctate signals in malignant melanocytes (c and f) and no signals above the background level in melanocytes of proliferative nodules (i and l).
Scale bars ¼ 1000 mm (a) and 50 mm (b).
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ules (Figure 2g, h, j, and k), which may
suggest or mimic melanoma on clinical
or histologic grounds (Yelamos et al.,
2015). The differential pattern for TERT
promoter methylation and telomerase
expression betweenmelanomas in GCN
and proliferative nodules demonstrated
in our study is consistent with the benign
clinical course of proliferative nodules
compared with the invariably aggressive
behavior of melanoma arising in GCN.
Further studies in a larger number of
patients are needed to determine the
potential diagnostic value of TERT pro-
moter methylation assays for ambiguous
proliferative lesions within GCN.
In our cohort, TERT promoter hyper-
methylation or promoter mutations
occurred in all melanoma samples but
in none of the benign or borderline
melanocytic lesions, suggesting that a
panel incorporating TERT promoter
methylation and mutation assays may
help discriminate between benign/
borderline and overtly malignantmelanocytic neoplasms. Future studies
need to assess the potential use of these
assays for diagnostic or prognostic
purposes in the clinic.
In summary, we demonstrate that in
subsets of malignant melanoma, TERT
is upregulated epigenetically by a
methylation-dependent mechanism.
These findings have potential thera-
peutic implications. TERT promoter
CpG hypermethylation is a reversible
phenomenon. Treatment with DNA
demethylating agents reduced TERT
expression and telomerase activity in
telomerase-positive cell lines (Guilleret
and Benhattar, 2003; Renaud et al.,
2007). Together, these findings provide
a rationale for developing a therapeutic
strategy in preclinical studies through
epigenetic modifications at TERT pro-
moter regulatory sites in melanomas
with the CpG island methylator
phenotype.
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Cutaneous wound healing is a complex
process requiring the coordination of
inflammatory cells, endothelial cells, fi-
broblasts, and keratinocytes (Gurtner
et al., 2008). Chronic wounds fail to
progress through this coordinated pro-
cess, and are often characterized by
prolonged inflammation, poor vascular-
ization, callus formation, and infection
(Bremet al., 2007;Martin et al., 2010). A
wide variety of advanced wound care
products have been developed to target
specific characteristics of chronic
wounds (Apelqvist, 2012). However, no
single therapy has yielded widespread
clinical success, and there is a critical
need to develop new biomarkers and
diagnostic technologies to evaluate
wound status and guide care.
Currently, wound closure is the
only accepted objective endpoint toevaluate wound treatments, and there is
a lack of quantitative surrogate bio-
markers to predict healing at earlier
stages. Multiphoton microscopy tech-
niques, such as two-photon excited
fluorescence (TPEF), have emerged as
useful approaches to evaluate epithelial
tissues and offer advantages in imaging
depths and signal collection over
confocal microscopy (Balu et al., 2013;
Varone et al., 2014). Through TPEF
imaging, the intrinsic fluorescence of
nicotinamide and flavin adenine di-
nucleotides (NADH and FAD) can be
measured without the application of
exogenous stains (Georgakoudi and
Quinn, 2012; Zipfel et al., 2003).
An optical redox ratio of FAD/
(NADHþFAD) autofluorescence has
been computed from a variety of cells
and tissues and is correlated with the
intracellular concentration ratio ofNADþ/NADH (Quinn et al., 2013;
Varone et al., 2014). This noninvasive
measure of the relative rates of glucose
catabolism to oxidative phosphoryla-
tion has been used to help diagnose
disease and evaluate tissue develop-
ment (Georgakoudi and Quinn, 2012).
Although metabolic stress at the sys-
temic and tissue level often coincides
with chronicity, the dynamics of meta-
bolism in the wound at the cellular level
are not well understood. Using label-
free multiphoton microscopy, the
objective of this study was to provide an
initial quantitative assessment of meta-
bolic biomarkers with sensitivity to dif-
ferences between nondiabetic and
diabetic wounds. To this end, multi-
photon imaging was performed on un-
stained sections of full-thickness
excisional wounds from the dorsum of a
streptozotocin-induced diabetic mouse
model. Animal studies were conducted
in accordance with Beth Israel
Deaconess Medical Center IACUC pro-
tocol #072-2012 and Tufts IACUC pro-
tocol #M2014-58. Additional methods’
